非小细胞肺癌姑息性胸部放疗:ASTRO循证指南2018更新
该指南更新基于系统检索的新证据,重点修订了不可治愈非小细胞肺癌(NSCLC)姑息性胸部外照射放疗(EBRT)时同步化疗(CC)的推荐。对于不适合根治性治疗但适合化疗、ECOG PS 0–2且预期生存≥3个月的III期NSCLC患者,推荐含铂双药化疗同步中度大分割姑息胸部放疗优于任一单独治疗;IV期NSCLC不推荐常规同步胸部放化疗。
要点
- III期不可治愈NSCLC符合化疗条件、PS 0–2、预期生存≥3个月者,推荐同步放化疗。
- IV期NSCLC不推荐常规使用同步胸部放化疗。
- 不可治愈NSCLC的最佳姑息治疗需要多学科协作。
核心结论
- 对明确亚组的不可治愈III期NSCLC,新证据支持姑息胸部EBRT同步化疗;其他不可治愈NSCLC证据仍不足。
研究设计与样本
- 基于系统PubMed检索发现关键问题新证据,工作组决定更新2011年ASTRO指南。
- 采用预设共识构建方法,并使用ASTRO批准的工具对证据质量和推荐强度进行分级。
主要发现
- 针对NSCLC姑息胸部EBRT联合CC的随机临床试验较少,但工作组对不可治愈III期和IV期NSCLC的推荐达成强共识。
- 对不适合根治性治疗但符合化疗条件、ECOG PS 0–2且预期生存≥3个月的III期NSCLC患者,推荐含铂双药化疗同步中度大分割姑息胸部放疗优于任一单独治疗。
- 对IV期NSCLC患者,不推荐常规使用同步胸部放化疗。
关键数值与推荐
- III期NSCLC推荐同步化疗需同时满足:不适合根治性治疗、适合化疗、ECOG PS 0–2、预期生存≥3个月。
- 推荐方案为含铂化疗双药同步中度大分割姑息胸部放疗,优于单纯化疗或单纯放疗。
- IV期NSCLC不推荐常规同步胸部放化疗。
临床怎么用
- 对不可治愈III期NSCLC,应评估化疗适宜性、ECOG PS和预期生存,筛选适合同步放化疗的患者。
- 对IV期NSCLC,不应常规采用同步胸部放化疗。
- 不可治愈NSCLC的姑息治疗应通过多学科协作制定方案。
局限性
- 针对NSCLC姑息胸部EBRT联合CC的随机临床试验较少。
- 除明确亚组外,其他不可治愈NSCLC患者的数据仍不足以支持该治疗方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. METHODS AND MATERIALS: Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline recommendations were created using a predefined consensus-building methodology supported by American Society for Radiation Oncology-approved tools for grading evidence quality and recommendation strength. RESULTS: Although few randomized clinical trials address the question of CC combined with palliative thoracic EBRT for non-small cell lung cancer (NSCLC), a strong consensus was reached among the task force on recommendations for incurable stage III and IV NSCLC. For patients with stage III NSCLC deemed unsuitable for curative therapy but who are (1) candidates for chemotherapy, (2) have an Eastern Cooperative Oncology Group PS of 0 to 2, and (3) have a life expectancy of at least 3 months, administration of a platinum-containing chemotherapy doublet concurrently with moderately hypofractionated palliative thoracic radiation therapy is recommended over treatment with either modality alone. For patients with stage IV NSCLC, routine use of concurrent thoracic chemoradiation is not recommended. CONCLUSIONS: Optimal palliation of patients with incurable NSCLC requires coordinated interdisciplinary care. Recent data establish a rationale for CC with palliative thoracic EBRT for a well-defined subset of patients with incurable stage III NSCLC. For all other patients with incurable NSCLC, data remain insufficient to support this treatment approach.
引用
- Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Pract Radiat Oncol. 2018. PMID: 29625898. doi:10.1016/j.prro.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。